GLP-1 Medications and Migraine: What the Research Shows

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. The studies described in this article were conducted primarily using FDA-approved branded versions of these drugs. Results may not apply to compounded formulations. This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting or changing any medication, especially if you have a history of migraine or other neurological conditions.*

---

Something unexpected keeps showing up in the data on GLP-1 medications.

People starting these treatments for weight management are reporting fewer migraines. Some who had struggled for years with high-frequency or chronic migraine are describing meaningful reduction in how often attacks occur. Researchers began noticing similar patterns in clinical settings, and they started asking a straightforward question: is this real, and if so, why?

The answer, based on research published between 2024 and 2026, is turning out to be more interesting than most people expected.

GLP-1 receptor agonists, the class of medications that includes semaglutide and tirzepatide, appear to interact with several of the biological pathways involved in migraine. And at least one pilot clinical study suggests the migraine benefits may be real, and independent of weight loss.

Here is what the current evidence shows, what it does not yet prove, and why it matters for anyone managing both obesity and migraine.

---

The Obesity-Migraine Connection

To understand why GLP-1 medications might affect migraines, it helps to start with what we know about obesity and headache disorders.

Migraine is not simply a severe headache. It is a complex neurological condition involving changes in brain signaling, inflammation in the trigeminovascular system, and alterations in pain processing. Obesity makes all of this worse.

People with obesity are significantly more likely to develop chronic migraine, defined as 15 or more headache days per month. They are also more likely to experience migraine progression - episodic migraine becoming chronic over time. The mechanisms behind this are multiple: increased systemic inflammation, higher circulating levels of the inflammatory cytokines that sensitize pain pathways, elevated intracranial pressure from increased abdominal fat, and disrupted sleep that lowers pain thresholds.

Weight loss, by any method, tends to reverse some of these drivers. A 2025 meta-analysis in Cureus by Mahran and colleagues reviewed evidence from bariatric surgery studies and found that significant weight reduction was associated with measurable improvements in migraine frequency and severity across multiple cohorts (PMID 41278056).

This background established an important baseline: the weight loss that GLP-1 medications produce could plausibly reduce migraine burden through these general metabolic mechanisms. But the newer research is pointing to something more direct.

---

Why GLP-1 Receptors Are Relevant to Migraine Biology

GLP-1 (glucagon-like peptide-1) is a hormone produced in the gut after eating. When people talk about GLP-1 medications, they are usually thinking about insulin regulation, appetite suppression, and gastric emptying. These are the mechanisms that drive weight loss.

But GLP-1 receptors are distributed throughout the brain and nervous system, not just the gut and pancreas. They are found in the hypothalamus, brainstem, and importantly, in regions that overlap with the pain-processing networks involved in migraine.

Two specific pathways are drawing the most research attention.

The Intracranial Pressure Pathway

Increased intracranial pressure (ICP) is strongly linked to both migraine and a condition called idiopathic intracranial hypertension (IIH), which causes severe chronic headaches in people with obesity. GLP-1 receptor agonists have been shown to reduce ICP - this is one of the primary reasons researchers began studying them in IIH patients, where they produce dramatic reductions in cerebrospinal fluid pressure.

Researchers at the University of Naples Federico II hypothesized that if elevated ICP plays a role in migraine (beyond full IIH), then drugs that lower ICP might offer migraine relief. This formed the rationale behind their landmark pilot study.

The CGRP Pathway

The second pathway involves calcitonin gene-related peptide, or CGRP. If you follow migraine research or have been prescribed one of the newer migraine prevention medications (erenumab, fremanezumab, galcanezumab), you have encountered CGRP. It is the neuropeptide that plays a central role in triggering and sustaining migraine attacks. The entire generation of anti-CGRP monoclonal antibody treatments is built around blocking it.

Research in animal models of chronic migraine has found that GLP-1 receptor agonists decrease CGRP expression in the relevant neural pathways. A 2024 systematic review in the Journal of Headache and Pain by Halloum and colleagues identified this as one of the mechanistic explanations for GLP-1's apparent analgesic properties across multiple pain conditions (PMID 38997662).

This means GLP-1 medications may be acting on one of the same biological targets as purpose-built migraine prevention drugs - not as powerfully or selectively, but through a pathway that clearly matters.

---

The Clinical Evidence: A Pilot Study With Striking Results

In 2025, researchers at the University of Naples Federico II published the first prospective clinical study specifically designed to test whether a GLP-1 receptor agonist could reduce migraine frequency in patients with obesity (PMID 40525593).

The study enrolled 31 patients with high-frequency or chronic migraine and obesity (BMI above 30), all of whom had already tried and failed at least two preventive migraine treatments. This is a population that is notoriously difficult to treat. Participants received liraglutide (a GLP-1 receptor agonist in the same class as semaglutide) at 1.2 mg daily for 12 weeks, as an add-on to their existing care.

The results were substantial.

Monthly migraine days dropped from an average of 19.8 at baseline to 10.7 after 12 weeks - a reduction of 9.1 days per month. This was statistically significant with a p-value below 0.001 and a large effect size (Cohen's d of 0.90).

The detail that makes this finding particularly notable: the improvement in migraine was not explained by weight loss. The average BMI change over the study period was just 0.1 kg/m2, which was not statistically significant. Statistical analysis confirmed that BMI reduction did not predict headache frequency reduction. The migraine improvement appeared to be a direct neurological effect of the medication, not a downstream result of losing weight.

The researchers excluded patients with confirmed IIH (identified by papilledema or other clinical signs), which means the migraine benefits observed were not simply IIH improvement in disguise.

---

What the Systematic Review Adds

The 2024 systematic review by Halloum and colleagues in the Journal of Headache and Pain analyzed 42 studies examining GLP-1 receptor agonists across multiple pain conditions (PMID 38997662). The review covered inflammatory pain, neuropathic pain, visceral pain, and headache disorders.

For headache specifically, the review found that GLP-1 receptor agonists showed analgesic effects through modulation of pain hypersensitivity in both animal models and human data. The mechanistic evidence pointed to multiple pathways, including effects on CGRP expression, reduction in neuroinflammation, and modulation of the trigeminovascular system that is central to migraine pathophysiology.

The review concluded that the therapeutic scope of GLP-1 receptor agonists is expanding beyond metabolic targets, and that their potential for headache and pain disorders warrants further dedicated clinical investigation.

---

An Important Safety Note: GLP-1 and Headache as a Side Effect

The picture is not entirely one of benefit. Headache is a known side effect of GLP-1 medications, particularly during dose titration in the early weeks of treatment. Most patients who experience this report that it resolves as their bodies adjust.

A 2025 review in Arquivos de Neuropsiquiatria by Ferreira and colleagues examined both sides of this relationship directly: when GLP-1 receptor agonists contribute to headache as a side effect, and when they appear to be therapeutic for chronic headache disorders (PMID 41145149). Their analysis reinforced that while transient headache is a recognized adverse effect during initiation, the longer-term picture for patients with obesity-related migraine may be meaningfully different.

One important case report from 2024 documented a patient with hemiplegic migraine (a rare and severe migraine subtype) whose attacks were exacerbated after starting a GLP-1 receptor agonist for weight loss (PMID 39118673). While a single case report cannot establish causation, it highlights a critical point: patients with known complex or atypical migraine conditions should discuss GLP-1 therapy carefully with a neurologist or headache specialist before starting treatment.

If you have a personal or family history of hemiplegic migraine, discuss this with your provider before beginning GLP-1 therapy.

---

What This Means for People With Migraine Considering GLP-1 Therapy

The research is at an early stage. The Naples pilot study enrolled 31 patients and ran for 12 weeks. No randomized controlled trials have yet been completed that specifically test GLP-1 medications as migraine prevention in patients without IIH. The systematic review draws on mechanistic and observational data, not head-to-head clinical trials.

What this means in practical terms:

If you have migraine and are considering GLP-1 therapy for weight management, this research is encouraging but not definitive. The migraine-related benefits are a plausible secondary effect, not a proven therapeutic indication.

If you have chronic or high-frequency migraine that has not responded to standard preventive treatments, and you also have obesity, this is worth discussing specifically with your provider. The pilot data suggests some patients in exactly that situation may see real benefit.

If you experience new or worsening headaches after starting GLP-1 therapy, this is worth reporting to your healthcare provider. It may reflect normal titration side effects, but it should be monitored, especially in the early weeks.

If you have a complex migraine history, including hemiplegic migraine, consult a neurologist before starting GLP-1 medications.

---

The Bigger Picture: GLP-1 and Neurological Inflammation

The migraine connection is part of a broader pattern that researchers are mapping in real time. GLP-1 receptor agonists are showing unexpected effects across multiple neurological and inflammatory conditions - including Alzheimer's disease research, idiopathic intracranial hypertension, Parkinson's disease, and now migraine.

The common thread across these findings is neuroinflammation. GLP-1 receptors in the brain appear to modulate inflammatory signaling in ways that have downstream effects on multiple neurological conditions that were not part of the original rationale for these drugs.

This does not mean GLP-1 medications are universal neurological treatments. The clinical evidence for most of these applications, including migraine, is preliminary. But it does suggest that these drugs are doing something meaningful in the brain beyond appetite regulation, and the scientific community is actively working to understand what that means therapeutically.

---

How Prescriva Approaches GLP-1 Therapy

Prescriva connects patients with licensed healthcare providers for medically supervised weight management using compounded GLP-1 medications. Our program includes an initial consultation, individualized treatment planning, and ongoing provider support.

Compounded semaglutide and tirzepatide are not FDA-approved, and are not approved for any neurological condition including migraine. If you have a history of migraine, your provider will take that into account during the medical evaluation.

If you have questions about whether GLP-1 therapy is appropriate for your situation, including how it may interact with any existing neurological conditions, this is exactly the kind of conversation to have during your consultation.

Ready to explore your options? Check your eligibility and start a conversation with a licensed provider.

---

*This article is for educational and informational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Results vary by individual. Always consult a qualified healthcare provider regarding any health condition or medication.*

---

Sources

1. Braca S, et al. Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: a prospective pilot study. *Headache.* 2025 Nov-Dec;65(10):1831-1838. PMID 40525593. [https://pubmed.ncbi.nlm.nih.gov/40525593/](https://pubmed.ncbi.nlm.nih.gov/40525593/)

1. Halloum W, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. *J Headache Pain.* 2024 Jul 12;25(1):112. PMID 38997662. [https://pubmed.ncbi.nlm.nih.gov/38997662/](https://pubmed.ncbi.nlm.nih.gov/38997662/)

1. Ferreira ET, Garcia LMP, Londero RG. Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom. *Arq Neuropsiquiatr.* 2025 Oct;83(10):1-7. PMID 41145149. [https://pubmed.ncbi.nlm.nih.gov/41145149/](https://pubmed.ncbi.nlm.nih.gov/41145149/)

1. Modestino EJ. Hemiplegic migraines exacerbated using an injectable GLP-1 agonist for weight loss. *Acta Sci Neurol.* 2024 May. PMID 39118673. [https://pubmed.ncbi.nlm.nih.gov/39118673/](https://pubmed.ncbi.nlm.nih.gov/39118673/)

1. Mahran M, et al. Effect of bariatric surgery on migraine headache: a systematic review and meta-analysis. *Cureus.* 2025 Nov. PMID 41278056. [https://pubmed.ncbi.nlm.nih.gov/41278056/](https://pubmed.ncbi.nlm.nih.gov/41278056/)